Details

Autor(en) / Beteiligte

• Brüggenwirth, Isabel M A
• Lantinga, Veerle A
• Rayar, Michel
• van den Berg, Aad P
• Blokzijl, Hans
• Reyntjens, Koen M E M
• Porte, Robert J
• de Meijer, Vincent E
• de Boer, Marieke T
• van den Boom, Anne Loes
• Buis, Carlijn I
• Fouraschen, Suomi MG
• Hoogwater, Frederik JH
• Klaase, Joost M
• de Kleine, Ruben H J
• Meerdink, Mark
• Nijkamp, Maarten W
• Rayar, A Michel
• Cuperus, Frans J C
• van der Heide, Frans
• van Vilsteren, Frederike G I
• Abbasova, Ilhama F
• Fernhout, Meine H
• Meyer, Peter
• Muskiet, Ernesto R R
• Vos, Jaap J
• Zeillemaker, Miriam
• Haring, Martijn P D
• Lascaris, Bianca
• Pamplona, Carol C
• Thorne, Adam M
• van Leeuwen, Otto B
• Lisman, Ton
• Bodewes, Silke B

Titel

Prolonged dual hypothermic oxygenated machine preservation (DHOPE-PRO) in liver transplantation: study protocol for a stage 2, prospective, dual-arm, safety and feasibility clinical trial

Ist Teil von

• BMJ open gastroenterology, 2022-01, Vol.9 (1), p.e000842

Ort / Verlag

England: BMJ Publishing Group Ltd

Erscheinungsjahr

2022

Quelle

EZB-FREE-00999 freely available EZB journals

Beschreibungen/Notizen

• IntroductionEnd-ischaemic preservation of a donor liver by dual hypothermic oxygenated machine perfusion (DHOPE) for 2 hours prior to transplantation is sufficient to mitigate ischaemia-reperfusion damage and fully restore cellular energy levels. Clinical studies have shown beneficial outcomes after transplantation of liver grafts preserved by DHOPE compared with static cold storage. In addition to graft reconditioning, DHOPE may also be used to prolong preservation time, which could facilitate logistics for allocation and transplantation globally.Methods and analysisThis is a prospective, pseudo-randomised, dual-arm, IDEAL-D (Idea, Development, Exploration, Assessment, Long term study-Framework for Devices) stage 2 clinical device trial designed to determine safety and feasibility of prolonged DHOPE (DHOPE-PRO). The end-time of the donor hepatectomy will determine whether the graft will be assigned to the intervention (16:00–3:59 hour) or to the control arm (4:00–15:59 hour). In total, 36 livers will be included in the study. Livers in the intervention group (n=18) will undergo DHOPE-PRO (≥4 hours) until implantation the following morning, whereas livers in the control group (n=18) will undergo regular DHOPE (2 hours) prior to implantation. The primary endpoint of this study is a composite of the occurrence of all (serious) adverse events during DHOPE and up to 30 days after liver transplantation.Ethics and disseminationThe protocol was approved by the Medical Ethical Committee of Groningen, METc2020.126 in June 2020, and the study was registered in the Netherlands National Trial Registry (https://www.trialregister.nl/) prior to initiation.Trial registration numberNL8740.